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John E. Levine,1 Sophie Paczesny,1 Stefanie Sarantopoulos2Acute and chronic graft-versus-host disease (aGVHD, cGVHD) are serious complications of allogeneic hema-
topoietic cell transplantation. The complex pathophysiology of these disease processes is associated with im-
mune system activation, the release of cytokines and chemokines, and alterations in cell populations. The
blood levels of specific protein and cellular levels in patients with GVHD have correlated with the
development, diagnosis, and prognosis of GVHD. Here, we review the most promising biomarkers for
aGVHD and cGVHD with clinical relevance. The utility of GVHD biomarkers in clinical care of allogeneic
hematopoietic cell transplantation recipients needs to be proven through clinical trials, and potential
approaches to trial design are discussed.
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Graft-versus-host disease (GVHD) remains the
most serious and challenging complication of alloge-
neic hematopoietic cell transplantation (HCT).
Despite advances in treatment and prevention, con-
cern over the morbidity and mortality of acute and
chronic GVHD (aGVHD, cGVHD) represents a bar-
rier to greater utilization of allogeneic HCT as
a potentially curative modality for patients with malig-
nant and nonmalignant diseases. New diagnostic and
therapeutic tools are needed to customize the delivery
of immunosuppressive drugs for optimal patient care.
To that end, there has recently been considerable
research effort devoted to the discovery and validation
of GVHD-relevant biomarkers. The paucity of vali-
dated biomarkers for aGVHD is partly because of
the complex pathology of GVHD that can be consid-
ered in a framework of three distinct sequential phases
of immune system cellular activation and cytokine pro-
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6/j.bbmt.2011.10.019cellular and protein levels in the GVHD patients’
blood [1]. GVHD is not only a systemic immunologic
disorder but also affects specific organ systems, includ-
ing the skin, gastrointestinal (GI) tract, and liver. The
clinical symptoms of the skin (maculopapular rash) and
of theGI tract (nausea, diarrhea) caused byGVHDcan
be difficult to distinguish from other causes (eg, infec-
tious, drug induced). Thus, biomarkers that are
GVHD and target organ specific may improve the
diagnosis, management, and prognosis of complica-
tions post-HCT. Potential applications include pre-
dicting response to treatment, defining new risk
strata that incorporate biomarker values, and initiating
preemptive therapy before onset of clinical symptoms.
The latter is particularly relevant to cGVHD, where
without objective biologically relevant measurements
of disease, rigorous clinical trials remain difficult to
conduct and interpret, and treatment remains pallia-
tive. Here, we review the current state of the science
of this rapidly evolving field.IDENTIFICATION OF ACUTE GVHD
BIOMARKERS
Advances in engineering have allowed for increased
data throughput, enabling the study of complete sets of
molecules (omics) with exponential speed, accuracy,
and cost-effectiveness. Thus, analysis of the entire
spectrum of molecular and cellular organization is
now possible, enabling researchers to gain insight
into the mechanism of diseases, with fewer a priori
assumptions [2]. Proteomics has certain advantages in
the study of aGVHD. First, proteins are more proxi-
mate than other cellular metabolites to the ongoing
Biol Blood Marrow Transplant 18:S116-S124, 2012 S117Clinical Applications for Biomarkers of aGVHD and cGVHDpathophysiology of this disease. Indeed, studies using
genomics, transcriptomics, and gene polymorphisms
incompletely correlate with the expression of function-
ally active proteins, which more accurately reflect
cellular cross-talk, such that it is likely that proteins
will provide the most ideal disease biomarkers [3,4].
Correlating the proteome with aGVHD has been
attempted by analysis of polypeptide fragments in the
urine [5] and the measurement of single potentially
informative proteins such as C-reactive protein [6,7]
or cytokeratin-18 [8]. A particularly successful strategy
that we have used has been the analysis of plasma
samples to identify multiple proteins differentially
expressed in patients with aGVHD. This technique,
called the Intact Protein Analysis System (IPAS),
matches the mass spectra in the plasma to a sequence
database to identify proteins. Briefly, plasma from
patients who never developed GVHD was pooled
together (GVHD-negative) as was plasma from
patients at the time that GVHD developed (GVHD-
positive). The GVHD-negative and GVHD-positive
pool were labeled with different carbon isotopes. The
two pools were combined, and specimens were sub-
jected to a two-dimensional protein fractionation pro-
cedure. The individual fractions were then digested
and analyzed on a new-generation liquid chromatogra-
phy tandemmass spectrometer. Because protein diges-
tion was performed in a top-down fashion before mass
spectrometry, the term ‘‘intact’’ protein analysis is used
[9]. The acquired spectra were automatically processed
by the high-throughput Computational Proteomics
Analysis System to identify proteins in the sample,
with a false discovery rate of\5% [10]. This resulted
in the identification of proteins with a range of concen-
trations spanning 7 logs [11].This techniquewas there-
fore able to detect low abundance proteins and is
quantitative, as each GVHD pool was labeled with
heavy and light stable isotopes. The list of proteins
identified by a mass spectrometer described previously
was then prioritized based on their degree of dysregu-
lation, as indicated by at least a 1.5-fold increase in
expression, the likelihood of involvement in GVHD
pathways based on known pathways and uniqueness
to the target organ that is associated with a given
GVHD type. Finally, we prioritized proteins with
available sandwich ELISA antibodies in order to facil-
itate the development of a GVHD blood test. A list of
candidate aGVHD biomarkers with diagnostic or
prognostic significance is shown in Table 1.VALIDATION OF AGVHD BIOMARKERS
Validation of putative GVHD biomarkers is usu-
ally performed with immunoassays rather than mass
spectrometry, and the sample set is created from
a cases-control repository involving large numbers ofsamples. This process should be done on a training
set, followed by an independent validation set; valida-
tion using sets from multiple institutions is ideal. The
final step of developing a clinical test uses the
biomarkers in the clinic, typically on thousands of sam-
ples. For high-throughput purposes and standardiza-
tion between laboratories, only immunoassays are
used at this step. Figure 1 describes the three steps of
the process required to translate candidate biomarkers
into a blood test.
In our initial validation studies, we used an anti-
body array approach to identify and sequential ELISA
to validate four systemic biomarkers that, when com-
bined into a GVHD biomarker panel, accurately dis-
criminated GVHD-negative from GVHD-positive
patients and carried prognostic significance [12]. Be-
cause biomarkers present at the time of GVHD diag-
nosis might be different between target organ-specific
GVHD, we also sought to identify biomarkers that
were specific forGVHDtarget organs to improve diag-
nostic and prognostic values of the systemic panel by
comparing patients with skin-specific GVHD or GI-
specific GVHD to patients without GVHD with
IPAS. It is possible that it could be difficult to find pro-
teins in the blood that are expressed in tissue, but be-
cause tissue proteins can leak into the blood stream, it
might be a reasonable endeavor. These are proteins
that normally function within cells but that can be re-
leased into plasma as a result of cell death or damage
[13]. To assess the validity of this approach, we com-
pared plasma pooled from 10 patients with skin-
specific GVHD to that from 10 controls in the first
IPAS run and plasma pooled from 10 patients with
GI tract-specific GVHD to 10 controls in a second
IPAS run. Elafin emerged as the lead biomarker candi-
date of skinGVHDat the time of clinical diagnosis, and
we showed that plasma elafin concentrations have sig-
nificant diagnostic and prognostic power, including
long-term survival, as a biomarker of skin GVHD
[14]. These data provide a proof-of-principle demon-
stration that biomarkers of disease-related tissue-
specific changes can be detected in the plasma of
patients. Using the same proteomics strategy, we dis-
covered regenerating-islet-derived-3-alpha (REG3a)
as a biomarker of lower GI GVHD and subsequently
validated it in two independent sets totaling 1,014 pa-
tients from three different centers. This marker pro-
vides important prognostic information, including
response to GVHD treatment and survival [15]. Physi-
cians are interested in both low- and high-risk groups
for predicting the development of GVHD and result-
ing clinical outcomes.Classical prognostic clinical out-
comes in aGVHD are maximum GVHD grade,
nonrelapse mortality (NRM), relapse mortality, and
overall survival (OS). For example, we analyzed
whether REG3a concentrations have prognostic sig-
nificance for patients presenting with lower GI
Table 1. Candidate Biomarkers of Acute GVHD with Diagnostic and Prognostic Significance
Protein Name Function Target Organ Diagnosis Prognosis
IL-2Ra Interleukin-2 receptor a chain,
CD25
Results from extracellular proteolyisis of the high-affinity receptor of IL2,
a key cytokine in the activation and proliferation of T cells.
Systemic Nakamura 2000 [60], Visentainer 2003 [61],
Shaiegan 2006 [62], Paczesny 2009 [12]
Paczesny 2009 [12]
IL-6 Interleukin-6 Functions in inflammation and the maturation of B cells. Systemic Malone 2007 [63]
IL-8 Interleukin-8 Mediator of the inflammatory response. Systemic Paczesny 2009 [12] Schots 2003 [64],
Paczesny 2009 [12]
IL-10 Interleukin-10 Pleiotropic effects in immunoregulation and inflammation; downregulates
expression of Th1 cytokines, MHC class II ags, and costimulatory
molecules on macrophages.
Systemic Liem 1998 [65]
IL-12 Interleukin-12 Secreted by antigen-presenting cells (particularly dendritic cells), required
for the T cell-independent induction of interferon (IFN)-g, important for
differentiation of Th1 and Th2 cells.
Systemic Nakamura 2000 [60], Mohty 2005 [66]
IL-15 Interleukin-15 Regulates T and natural killer cell activation and proliferation Systemic Sakata 2001 [67]
IL-18 Interleukin-18 Proinflammatory cytokine that augments natural killer cell activity
and stimulates IFN-g production in Th1 cells.
Systemic Nakamura 2000 [60], Shaiegan 2006 [62],
Fujimori 2000 [68]
CCL8 Chemokine (C-C motif)
ligand 8
Chemokine attracting monocytes, lymphocytes, basophils and eosinophils
to inflamed sites.
Systemic Hori 2008 [69]
CXCL10 Chemokine (C-X-C motif)
ligand 10
Ligand for the receptor CXCR3, binding results in pleiotropic effects,
including stimulation of monocytes, natural killer and T cell migration,
and modulation of adhesion molecule expression.
Systemic Piper 2007 [70]
TNFa Tumor necrosis factor (TNF)a Key proinflammatory cytokine, secreted by macrophages Systemic Holler 1990 [71], Symington 1990 [72],
Imamura 1994 [73]
TNFR-1 Tumor necrosis factor receptor-1 Expressed by all human tissues and is the major signaling receptor for TNFa Systemic Or 1996 [74], Choi 2008 [52],
Paczesny 2009 [12]
Paczesny 2009 [12]
HGF Hepatocyte growth factor Regulator of cell growth, motility, and morphogenesis, secreted by
mesenchymal cells.
Systemic/GI tract Paczesny 2009 [12], Sakata 2001 [67] Paczesny 2009 [12]
KRT18 Cytokeratin-18 fragments Induction of apoptosis results in early cleavage of KRT18 by caspases. GI tract Luft 2007 [8]
PI3 Elafin Proteinase expressed by keratinocytes and involved in local innate
immune defense.
Skin Paczesny 2010 [15] Paczesny 2010 [15]
REG3a Regenerating islet-derived 3 a Protein expressed by intestinal Paneth cells, direct antimicrobial activity. GI tract Harris 2011 [16] Harris 2011 [16]
IFN-g indicates Interferon.
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Figure 1. Biomarker research steps.
Biol Blood Marrow Transplant 18:S116-S124, 2012 S119Clinical Applications for Biomarkers of aGVHD and cGVHDGVHD and hypothesized that the REG3a concentra-
tion at GVHD diagnosis would also correlate with
NRM. We therefore divided the 162 patients into
two equal groups based on themedian REG3a concen-
tration: high (.151 ng/mL, n5 81) and low (#151 ng/
mL, N5 81). NRM was twice as high in patients with
high REG3a concentrations, and this difference
remained significant after adjusting for known risk fac-
tors of donor type, degree ofHLAmatch, conditioning
intensity, age, and baseline disease severity. The inci-
dence of relapse mortality was comparable for both
groups, and thus patients with high REG3a concentra-
tions at the time of GVHD diagnosis experienced
significantly inferior OS [15].IDENTIFICATION ANDVALIDATION
OF CGVHD BIOMARKERS
At the first meeting of the NIH biomarker consen-
sus group in 2006, the ideal cGVHD biomarker was
formally defined [16,17]. Several inflammatory
markers and cytokines such as transforming growth
factor-b1, tumor necrosis factor, and interferon-g,
that are increased in aGVHD, have been identified as
candidate biomarkers for cGVHD, but none has
been developed for clinical use. Genetic markers of
cGVHD development have also been proposed, such
as major histocompatibility complex class I chain-
related protein A-129 genotype and the negative regu-
lator of T cell costimulation CTLA-4 149 A/G*GG
genotype, but the significance of these remains un-
known [18,19]. Currently, there are no validated
biomarkers for cGVHD.
cGVHD pathophysiology remains inextricably
linked to graft-versus-leukemia in patients [20], thus
further complicating efforts to define a predictive bio-
marker for this disease [20]. T cell responses directed
at minor histocompatibility antigens are vital to
cGVHDpathogenesis. Recognition of B cell autoreac-
tivity likely emanating from inciting T cell alloreactiv-ity in cGVHD [21-24] sparks continued interest in
antibody responses in patients [24]. When human B
cell responses to alloantigens were characterized and
correlated with cGVHD development, a resurgence
of interest in B cell subsets and potential factors that
drive B cells in this disease ensued [25-27]. Extensive
reviews of candidate biomarkers have been recently
published [28,29]. Thus, we will focus on newly
elucidated B cell-activating factor (BAFF) and B cell
pathophysiology that may inform larger-scale efforts
aimed at candidate biomarker validation in cGVHD.
BAFF and Human cGVHD
Characterization of the tumor necrosis factor fam-
ily member BAFF changed the way we think about B
cell autoreactivity [30] and led to the discovery of sig-
nificantly elevated BAFF levels in patients with active
cGVHD [21,32]. Ease of measurement, accessibility
of plasma samples from patients, and preliminary
data suggesting that significant elevation of BAFF
preceded cGVHD development [31] make soluble
BAFF a tempting biomarker. In a prospective study
of new-onset cGVHD in 52 children and 28 control
patients who never developed cGVHD, BAFF levels
were elevated in patients with cGVHD that developed
regardless of time of onset post-HCT, and these levels
decline in patients who show clinical response to treat-
ment [32]. Anti-dsDNA antibodies were also elevated
in patients who developed cGVHD, confirmatory of
previous reports [24] and further implicating the im-
portance of B cells in cGVHD activity.
Measurement of soluble BAFF by itself is compli-
cated by several factors: (1) BAFF is increased in the set-
ting of B lymphopenia [33,34], (2) BAFF levels are low in
patients taking high-dose steroids [31], and (3) precise
quantification of BAFF is challenging because BAFF
may exist in an oligomeric form that is understimated
using current ELISA [35]. Even without precise quanti-
fication, significantly increased BAFF levels are found
in cGVHD patients as well as significantly higher
BAFF/B cell ratios [36,37]. Further corroborating the
relevance of BAFF in cGVHD pathophysiology and
potentially pointing to novel genotypic predictive
markers of disease is the reported increased frequency
of BAFF polymorphisms in HCT recipients who
developed cGVHD. Whether these genetic differences
confer increased BAFF production remains to be
determined [38].
Robust B Cell Reconstitution: A Few Good B
Cells in Human cGVHD
Poor B cell reconstitution in cGVHD linked to im-
mune deficiency has been well described [39,40]. B cell
numbers are not lower than normal in cGVHD, but
they are lower compared with healthy post-HCT pa-
tients. That is, a well-described supranormal ‘‘surge’’
Figure 2. Biologically relevant BAFF and B cell markers in plasma, blood, and bone marrow. (A) Naive and transitional B cells are increased in patients
without cGVHD, and these may serve as predictive markers of good post-HSCT health. (B) Low transitional and naive B cell numbers and high BAFF/B
cell ratios may serve as markers of cGVHD.
S120 Biol Blood Marrow Transplant 18:S116-S124, 2012J. E. Levine et al.in naive B cell number found after lymphopenia induc-
tion in the healthy state is absent in cGVHD patients
[41,42]. Transitional B cells, which bridge newly
formed B cells in the bone marrow and peripheral
maturation, circulate in the peripheral blood and have
been defined in humans [43]. These human transitional
subsets defined using IgD1 and CD38Hi, CD272 pop-
ulations are increased to supranormal numbers in pa-
tients who never develop cGVHD [37], suggesting
return toB cell homeostasis is vital to a nonautoimmune
phenotype in cGVHD [44].
Other B cell subsets identified using CD21 and
additional markers of murine transitional B cells were
found to be increased in cGVHD patients [45]. Inter-
estingly, decreased proportions of CD191CD21lo cells
before extracorporeal photopheresis correlated with
positive treatment outcomewith extracorporeal photo-
pheresis [46]. Subsequent analysis revealed a relative
decrease in this cell population in those cGVHD
patients with hypogammaglobulinemia [36].
The association of clinical decline in cGVHD
patients who failed to reconstitute the naive B cell
compartment after rituximab [47] suggests that altered
B cell homeostasis because of diminished bonemarrow
B cell production capacity is critical. To further exam-
ine this, Fedoriw et al. [48] studied 30 patients who at
a median post-HSCT follow-up time of 2 years, had
developed cGVHD (n 5 15) or never developed
(n 5 15) cGVHD. Bone marrow biopsies obtained
approximately 1 month after HSCT revealed signifi-
cantly fewer B cell precursors in the patients who later
developed cGVHD (median 5 2 versus 44 cells/hpf;
P 5 .0007), and the difference was maintained after
patients on high-dose steroid therapy were excluded
(median 5 20 versus 49 cells/hpf; P 5 .0170) [48].
These data suggest that decreased precursor B cells
in bone marrow may be predictive of cGVHD devel-
opment, while increased precursor B cells in the mar-
row and/or increased transitional and naive B cells in
the blood may be predictors of a healthy post-HSCToutcome. Taken together, current evidence suggests
examination of BAFF and B cells in blood and bone
marrow may lead to testable biomarker candidates
for good health after HSCT (Figure 2A).
A Few Bad B Cells in Human cGVHD
Improved understanding of B cell subsets in sec-
ondary lymphoid organs and in autoimmune diseases
enabled identification of uniquely circulating B cell
subsets in cGVHD [49]. Decreased numbers of naive
and transitional B cells result in a proportional increase
in potentially autoreactive, antigen-experienced cells
marked by cell surface CD271 expression [37,50].
The CD271 B cell population in autoimmune states
is distinct from those antimicrobial ‘‘memory’’ B cells
typically found in healthy individuals. In HCT
patients with cGVHD, we find that this population is
activated and capable of ex vivo constitutive IgG
secretion [37]. A subset of CD271 B cells (pregerminal
center and plasmablast-like cells) uniquely circulate in
diseased patients, including cGVHD patients [37,51].
The pregerminal center population in cGVHD is of
particular interest given the high expression of two
important BAFF receptors found on these cells,
further suggesting their potential pathologic role [37].
Prospective serial analysis of these B cell receptor-
activated CD271 B cell subsets is warranted to deter-
mine whether their presence associates with cGVHD
onset, severity, or treatment response (Figure 2B).INCORPORATING GVHD BIOMARKERS
IN CLINICALTRIALS
Given the progress being made in GVHD bio-
marker identification and validation, it is not surpris-
ing that clinical trial design will begin incorporating
biomarkers. As an example, tumor necrosis factor
receptor-1 (TNFR1) levels were shown to be elevated,
relative to pre-HCT baseline, on day 7 post-HCT in
Figure 3. Possible randomized, double-blinded, placebo-controlled, trial design to test GVHD preemption.
Biol Blood Marrow Transplant 18:S116-S124, 2012 S121Clinical Applications for Biomarkers of aGVHD and cGVHDpatients who later went on to develop aGVHD after
myeloablative conditioning regimens [52]. In this
study, the degree of change in TNFR1 levels strongly
correlated with the timing and severity of aGVHD as
well as NRM and OS. The outcome implications
were particularly relevant in the 171 patients who
underwent HCT from an unrelated donor, in that
patients with high TNFR1 levels on day 7 post-
HCT were much more likely to experience nonrelapse
death in the first post-HCT year (49% versus 28%;
P5 .01), translating into a significant difference in sur-
vival at 1 year. These findings led to the development
of a clinical trial that added the tumor necrosis
factor-inhibitor etanercept to a standard tacrolimus/
methotrexate GVHD prophylaxis regimen for recipi-
ents of myeloablative unrelated donor HCT. In this
prospective clinical trial, etanercept effectively pre-
vented the expected rise in TNFR1 levels in patients
receiving nontotal-body irridiation-based condition-
ing regimens but interestingly not in recipients of
total-body irridiation-based conditioning. The
patients who received nontotal-body irridiation-based
conditioning unrelated donor HCT experienced
attenuated forms of GVHD (primarily steroid-
responsive skin GVHD), relatively low rates of
1-year NRM (16%), and high 1-year survival (69%)
[53]. In light of the finding that a single biomarker,
TNFR1, had predictive value for onset of aGVHD,
we tested whether other potentially informative bio-
markers (IL2Ra and elafin) could be combined with
TNFR1 into a predictive GVHD biomarker panel.
Levels of each biomarker was assessed at day 7 and
day 14 post-HCT in 513 patients who had undergone
unrelated HCT and had not yet developed GVHD
[54]. Following its discovery as a GI-GVHD-specific
biomarker, reg3awas also assayed, and additional sam-
ples from day 21 and 28 in patients without GVHD
were included. The endpoint was the development of
grade II-IV aGVHD by day 56 post-HCT. Day 56was chosen under the assumption that the plasma pro-
teome at a given time point would not reliably predict
the occurrence of events many weeks or months later.
After testing different biomarker combinations, a final
panel consisting of IL2Ra, TNFR1, and reg3a was
found to have strong predictive value. Patients can be
categorized as at high risk on a weekly basis, up until
day 28 for GVHD occurring within the first 2 months
post-HCT. As with any screening test, improvements
in sensitivity come at the expense of specificity and vice
versa, and which aspect to emphasize is a matter of
clinical judgment. The experience with post-HCT
CMV disease offers an instructive example in how
the transplant community approached this sort of
problem. Before the development of cytomegalovirus
(CMV) predictive tests, the incidence of CMV disease
was 35%, with high mortality rates. The introduc-
tion of CMV preemptive strategies guided by poly-
merase chain reaction or antigenemia studies reduced
CMV disease to 5% to 15% [55]. Extrapolating
from published data of the number of positive CMV
screening tests compared with the expected number
of cases of CMV disease, it appears that 50% of pos-
itive CMV screens, if untreated, would not result in
CMV disease [56,57]. The sensitivity of CMV
screening tests is very high, in the range of 90%,
meaning that relatively few cases of CMV disease
develop in the absence of a positive screening test.
Thus, it has become common practice to administer
preemptive therapy to patients who were not likely to
develop CMV disease in order to effectively prevent
CMV disease cases. If we applied a similar standard to
GVHD preemptive therapy (1:1 true positive to false
positive), the sensitivity of the three-biomarker
GVHD prediction panel is 67%. Although not yet as
accurate as the gold standard, CMV screening, we
believe that these results are sufficient to design
a clinical trial to test whether a preemptive strategy
would prevent GVHD. The toxicity of the
S122 Biol Blood Marrow Transplant 18:S116-S124, 2012J. E. Levine et al.intervention is an important consideration in trial
design, as excess toxicity from preemption will
dampen acceptance of the strategy. A short course of
corticosteroid therapy at the time that markers of
alloreactivity are increasing may be a reasonable
therapy to test. The success of preemption will need to
include not only any reduction in the incidence of
GVHD but also any increase infectious complications
and relapses that may occur. Ultimately, a randomized
trial will be needed to assess the effectiveness of
GVHD preemption. A possible randomized trial
design is illustrated inFigure 3.The trial design assumes
a GVHD grade II-IV incidence of 44% and that the
intervention to preempt GVHD is successful 50% of
the time. The biomarker panel to predict GVHD has
a sensitivity of 66% and specificity of 50%. Given these
parameters, 57% of patients will be categorized as high
risk for GVHD. All patients receive a treatment, either
placebo or intervention. Patients categorized as low risk
for GVHD (43%), that is, weekly biomarker panel
results from day 7 to day 28 do not predict for
GVHD, receive placebo alone. The expected GVHD
incidence in the low-risk patients is 36%. Patients cate-
gorized as high risk for GVHD based on a positive bio-
marker panel result are randomized to either placebo or
the intervention.Patients randomized toplacebo should
be twice as likely to develop GVHD as the intervention
group (54% versus 27%). The difference in GVHD
rates between the two placebo groups (54% versus
36%) is because of overrepresentation of GVHD in
the high-risk, placebo-treated arm.
Another potential clinical application of GVHD
biomarkers is to use them to risk stratify patients at
the time of GVHD onset. GI GVHD is considered
a high-risk feature in the GVHD grading system, but
given the absence of further risk stratification, the stan-
dard of care for all patients with GI GVHD is prompt
initiation of systemic steroid treatment, with the addi-
tion of second-line agents reserved for patients who
fail frontline therapy. Unfortunately, most patients
who require second-line therapy die, highlighting the
need for refinement of risk beyond what the current
grading system provides. We have recently developed
a risk stratification algorithm for patients with
new-onset GI GVHD that incorporates clinical stage,
histologic grade, and plasma levels of the newly discov-
ered GI GVHD biomarker, reg3a. This easy-to-use
algorithm assigns one equal weight point to each of
the three individual risk factors: clinical stage .1, his-
tologic grade .3, and reg3a level .151 ng/mL.
Patients with two or more risk factors at onset were
less likely to respond to treatment, and this translated
into highly significant differences in NRM. Patients
with two or three risk factors (high risk) at the onset
of clinical manifestations of GI GVHD experience
1-year NRM rates of 71%, whereas patients who pres-
ent with 0 or 1 risk factor (standard risk) experience1-year NRM rates of 30% (P\ .0001). Early identifi-
cation of patients at high risk for treatment unrespon-
siveness may permit testing alternative therapies
before refractory disease develops.
Preemptive strategies for cGVHD, similar to those
discussed for aGVHD mentioned previously, are also
being designed. Given the correlation between B
cell-related biomarkers and the development of
cGVHD, together with clinical data supporting the
use of rituximab to prevent cGVHD [58], there is
a Canadian trial under design that will administer
rituximab to children identified as high risk for devel-
opment of cGVHD on the basis of biomarker assays
(K. Schultz, personal communication). The advent of
the cGVHD consortium is likely to spur additional
research endeavors along these lines [59].ACKNOWLEDGMENTS
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